nach oben

Die Kardiologie

Erschienen in:

15.02.2024 | Statine | CME

Statine: Nebenwirkungen – alternative Therapieoptionen

verfasst von: Dr. med. Umidakhon Makhmudova, Prof. Dr. Oliver Weingärtner

Erschienen in: Die Kardiologie | Ausgabe 2/2024

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Statine gelten als Erstlinientherapieoption zur Behandlung von Hypercholesterinämie. Laut Daten aus einer globalen Metaanalyse wird die Inzidenz von Statinintoleranz auf unter 10 % geschätzt. Statinassoziierte muskuläre Schmerzen (SAMS) sind dabei die häufigsten Nebenwirkungen von Statinen. Ein erheblicher Teil der SAMS ist jedoch auf den Noceboeffekt zurückzuführen. Eine umfassende Aufklärung über den prognostischen Nutzen von Statinen sowie eine detaillierte Anamnese und Diagnostik zur Identifizierung der Risikofaktoren für SAMS sind entscheidend, um diese Nebenwirkung zu vermeiden. Falls trotz dieser Maßnahmen Nebenwirkungen bestehen oder individuelle LDL(Low-Density-Lipoprotein)-C(Cholesterin)-Zielwerte nicht erreicht werden, stehen alternative Therapieoptionen zur Verfügung. Die individuelle Variabilität in der LDL-C-Senkung unter allen lipidsenkenden Medikamenten betont die Notwendigkeit einer präzisen, individualisierten Therapie.

Jasilionis D, van Raalte AA, Klüsener S, Grigoriev P (2023) The underwhelming German life expectancy. Eur J Epidemiol 38:839–850PubMedPubMedCentralCrossRef

The Global Cardiovascular Risk Consortium et al (2023) Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med 389:1273–1285CrossRef

Mach F et al (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188PubMedCrossRef

Weingärtner O et al (2020) Kommentar zu den Leitlinien (2019) der ESC/EAS zur Diagnostik und Therapie der Dyslipidämien. Kardiologe 14:256–266CrossRef

Laufs U, Weingärtner O, Kassner U, Schatz U (2022) State of the Art: Therapie mit Statinen. Dtsch Med Wochenschr 147:62–68PubMedCrossRef

Weingärtner O, Marx N, Klose G, Laufs U (2022) Therapieoptionen zur LDL-C-Senkung zusätzlich zu Statinen. Dtsch Med Wochenschr 147:1001–1012PubMedCrossRef

Braunwald E (2022) How to live to 100 before developing clinical coronary artery disease: a suggestion. Eur Heart J 43:249–250PubMedCrossRef

Fong CW (2014) Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3‑hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies. Eur J Med Chem 85:661–674PubMedCrossRef

Lütjohann D, Stellaard F, Mulder MT, Sijbrands EJG, Weingärtner O (2019) The emerging concept of ‘individualized cholesterol-lowering therapy’: a change in paradigm. Pharmacol Ther 199:111–116PubMedCrossRef

10.

Pedro-Botet J et al (2001) Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 158:183–193PubMedCrossRef

11.

Zimmermann F et al (2020) Impact of the gut microbiota on atorvastatin mediated effects on blood lipids. J Clin Med 9:1596PubMedPubMedCentralCrossRef

12.

Karlson BW et al (2016) Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother 2:212–217PubMedCrossRef

13.

Oesterle A, Laufs U, Liao JK (2017) Pleiotropic effects of statins on the cardiovascular system. Circ Res 120:229–243PubMedPubMedCentralCrossRef

14.

Cholesterol Treatment Trialists’ (CTT) Collaboration (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 376:1670–1681CrossRef

15.

Shepherd J et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301–1308PubMedCrossRef

16.

Kashef MA, Giugliano G (2017) Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS). Glob Cardiol Sci Pract. https://doi.org/10.21542/gcsp.2016.35CrossRef

17.

Cheeley MK et al (2022) NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol 16:361–375PubMedCrossRef

18.

Bytyçi I et al (2022) Prevalence of statin intolerance: a meta-analysis. Eur Heart J. https://doi.org/10.1093/eurheartj/ehac015CrossRefPubMedPubMedCentral

19.

Banach M et al (2015) Statin intolerance—an attempt at a unified definition. Position paper from an international lipid expert panel: this paper is also published in parallel in archives of medical science. Expert Opin Drug Saf 14:935–955PubMedCrossRef

20.

Mancini GBJ et al (2016) Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus working group update (2016). Can J Cardiol 32:S35–S65PubMedCrossRef

21.

Rosenson RS (2020) Definitions of statin-associated muscle symptoms. In: Thompson PD, Taylor BA (Hrsg) Statin-associated muscle symptoms. Springer, S 27–33 https://doi.org/10.1007/978-3-030-33304-1_4CrossRef

22.

Ward NC, Watts GF, Eckel RH (2019) Statin toxicity: mechanistic insights and clinical implications. Circ Res 124:328–350PubMedCrossRef

23.

Warden BA et al (2023) Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the national lipid association. J Clin Lipidol 17:19–39PubMedCrossRef

24.

Howard JP et al (2021) Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol 78:1210–1222PubMedPubMedCentralCrossRef

25.

Wood FA et al (2020) N‑of‑1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med 383:2182–2184PubMedCrossRef

26.

Reith C et al (2022) Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet 400:832–845CrossRef

27.

Stürzebecher PE, Schumann F, Kassner U, Laufs U (2022) Statinintoleranz und statinassoziierte Muskelschmerzen. Herz 47:204–211PubMedPubMedCentralCrossRef

28.

Makhmudova U et al (2023) Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (“Jena auf Ziel”). Clin Res Cardiol. https://doi.org/10.1007/s00392-022-02147-3CrossRefPubMedPubMedCentral

29.

Taylor BA, Thompson PD (2016) Statins and their effect on PCSK9—impact and clinical relevance. Curr Atheroscler Rep 18:46PubMedCrossRef

30.

Ridker PM, Mora S, Rose L, JUPITER Trial Study Group (2016) Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J 37:1373–1379PubMedPubMedCentralCrossRef

31.

Colhoun HM et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696PubMedCrossRef

32.

Sattar N et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375:735–742PubMedCrossRef

33.

Navarese EP et al (2013) Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 111:1123–1130PubMedCrossRef

34.

Olmastroni E et al (2022) Statin use and risk of dementia or Alzheimer’s disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiolog 29:804–814CrossRef

35.

Zhou Z et al (2021) Effect of statin therapy on cognitive decline and incident dementia in older adults. J Am Coll Cardiol 77:3145–3156PubMedCrossRef

36.

Björnsson E, Jacobsen EI, Kalaitzakis E (2012) Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 56:374–380PubMedCrossRef

37.

Newman CB et al (2019) Statin safety and associated adverse events: a scientific statement from the American heart association. ATVB. https://doi.org/10.1161/atv.0000000000000081CrossRef

38.

Authors & Collaborators (2022) Updated S2k clinical practice guideline on non-alcoholic fatty liver disease (NAFLD) issued by the German society of gastroenterology, digestive and metabolic diseases (DGVS). Z Gastroenterol 60:e733–e801 (AWMF Registration No.: 021-025)CrossRef

39.

Collins R et al (2016) Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388:2532–2561PubMedCrossRef

40.

McKinney JS, Kostis WJ (2012) Statin therapy and the risk of Intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke 43:2149–2156PubMedCrossRef

41.

Ribe AR et al (2020) Statins and risk of intracerebral hemorrhage in individuals with a history of stroke. Stroke 51:1111–1119PubMedCrossRef

42.

Yin Y, Zhang L, Marshall I, Wolfe C, Wang Y (2022) Statin therapy for preventing recurrent stroke in patients with Ischemic stroke: a systematic review and meta-analysis of randomized controlled trials and observational cohort studies. Neuroepidemiology 56:240–249PubMedCrossRef

43.

Amarenco P et al (2020) A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med 382:9–19PubMedCrossRef

44.

Altmann SW et al (2004) Niemann-pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 303:1201–1204PubMedCrossRefADS

45.

Betters JL, Yu L (2010) NPC1L1 and cholesterol transport. FEBS Lett 584:2740–2747PubMedPubMedCentralCrossRef

46.

Myocardial Infarction Genetics Consortium Investigators et al (2014) Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 371:2072–2082CrossRef

47.

Geach T (2015) NPC1L1 mutations lower CHD risk. Nat Rev Cardiol 12:3–3PubMedCrossRef

48.

Sudhop T et al (2002) Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106:1943–1948PubMedCrossRef

49.

Ballantyne C (2002) Ezetimibe: efficacy and safety in clinical trials. Eur Heart J Suppl 4:J9–J18CrossRef

50.

Cannon CP et al (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372:2387–2397PubMedCrossRef

51.

Ouchi Y et al (2019) Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial. Circulation 140:992–1003PubMedCrossRef

52.

Kim B‑K et al (2022) Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet 400:380–390PubMedCrossRef

53.

Nissen SE et al (2023) Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 388:1353–1364PubMedCrossRef

54.

Warden BA, Cardiology B‑A, Purnell JQ, Duell PB, Fazio S (2022) Real-world utilization of bempedoic acid in an academic preventive cardiology practice. J Clin Lipidol 16:94–103PubMedCrossRef

55.

Ballantyne CM et al (2022) Factors associated with enhanced low-density lipoprotein cholesterol lowering with bempedoic acid. JAHA 11:e24531PubMedPubMedCentralCrossRef

56.

Kent ST et al (2017) PCSK9 loss-of-function variants, low-density lipoprotein cholesterol, and risk of coronary heart disease and stroke: data from 9 studies of blacks and whites. Circ Cardiovasc Genet. https://doi.org/10.1161/circgenetics.116.001632CrossRefPubMedPubMedCentral

57.

Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264–1272PubMedCrossRef

58.

Langsted A, Nordestgaard BG, Benn M, Tybjærg-Hansen A, Kamstrup PR (2016) PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis. J Clin Endocrinol Metab 101:3281–3287PubMedCrossRef

59.

Schwartz GG et al (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379:2097–2107PubMedCrossRef

60.

Blom DJ et al (2014) A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 370:1809–1819PubMedCrossRef

61.

Sabatine MS et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713–1722PubMedCrossRef

62.

Ray KK et al (2023) Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: final results from the European observational HEYMANS study. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2023.01.002CrossRefPubMed

63.

Qamar A et al (2019) Interindividual variation in low-density lipoprotein cholesterol level reduction with evolocumab: an analysis of FOURIER trial data. JAMA Cardiol 4:59–63PubMedCrossRef

64.

Desai NR et al (2017) Association between circulating baseline proprotein convertase subtilisin kexin type 9 levels and efficacy of evolocumab. JAMA Cardiol 2:556PubMedPubMedCentralCrossRef

65.

Ray KK et al (2020) Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 382:1507–1519PubMedCrossRef

66.

Lamb YN (2021) Inclisiran: first approval. Drugs 81:389–395PubMedPubMedCentralCrossRef

67.

Dyrbuś K, Gąsior M, Penson P, Ray KK, Banach M (2020) Inclisiran-new hope in the management of lipid disorders? J Clin Lipidol 14:16–27PubMedCrossRef

68.

Sinning D, Landmesser U (2020) Low-density lipoprotein-cholesterol lowering strategies for prevention of atherosclerotic cardiovascular disease: focus on siRNA treatment targeting PCSK9 (Inclisiran). Curr Cardiol Rep 22:176PubMedPubMedCentralCrossRef

69.

Makhmudova U et al (2023) High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany. Clin Res Cardiol. https://doi.org/10.1007/s00392-023-02247-8CrossRefPubMedPubMedCentral

70.

Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE (2023) First clinical experiences with inclisiran in a real-world setting. J Clin Lipidol. https://doi.org/10.1016/j.jacl.2023.09.005CrossRefPubMed

71.

Brandts J, Ray KK (2023) Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. Nat Rev Cardiol. https://doi.org/10.1038/s41569-023-00860-8CrossRefPubMed

72.

Kingwell K (2022) Base editors hit the clinic. Nat Rev Drug Discov 21:545–547PubMedCrossRef

73.

Johns DG et al (2023) Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.122.063372CrossRefPubMedPubMedCentral

74.

Ballantyne CM et al (2023) Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol 81:1553–1564PubMedCrossRef

75.

Mead J, Irvine S, Ramji D (2002) Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 80:753–769PubMedCrossRef

76.

Ginsberg HN, Goldberg IJ (2023) Broadening the scope of dyslipidemia therapy by targeting APOC3 (apolipoprotein C3) and ANGPTL3 (angiopoietin-like protein 3). ATVB 43:388–398CrossRef

77.

Adam RC et al (2020) Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. J Lipid Res 61:1271–1286PubMedPubMedCentralCrossRef

78.

Dewey FE et al (2017) Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med 377:211–221PubMedPubMedCentralCrossRef

79.

Wu L, Soundarapandian MM, Castoreno AB, Millar JS, Rader DJ (2020) LDL-cholesterol reduction by ANGPTL3 inhibition in mice is dependent on endothelial lipase. Circ Res 127:1112–1114PubMedPubMedCentralCrossRef

80.

Raal FJ et al (2020) Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med 383:711–720PubMedCrossRef

81.

(2022) Pfizer and Ionis announce discontinuation of vupanorsen clinical development program. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-ionis-announce-discontinuation-vupanorsen

82.

Gaudet D et al (2020) Vupanorsen, an N‑acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J 41:3936–3945PubMedPubMedCentralCrossRef

83.

Watts GF et al (2020) RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia. Eur Heart J. https://doi.org/10.1093/ehjci/ehaa946.3331CrossRefPubMedPubMedCentral

84.

Arrowhead Pharmaceuticals. (2021) Study of ARO-ANG3 in adults with mixed dyslipidemia (ARCHES-2). https://www.clinicaltrials.gov/ct2/show/NCT04832971

85.

Arrowhead Pharmaceuticals (2022) Study of ARO-ANG3 in participants with homozygous familial hypercholesterolemia (HOFH). https://clinicaltrials.gov/ct2/show/NCT05217667

Titel: Statine: Nebenwirkungen – alternative Therapieoptionen
verfasst von: Dr. med. Umidakhon Makhmudova
Prof. Dr. Oliver Weingärtner
Publikationsdatum: 15.02.2024
Verlag: Springer Medizin
Schlagwörter: Statine
Hypercholesterinämie
Lipidstoffwechselstörungen
Ezetimib
Atorvastatin
PCSK9-Hemmer
Prävention und Rehabilitation in der Kardiologie
Herz-Kreislauf-Erkrankungen in der Hausarztpraxis
Erschienen in: Die Kardiologie / Ausgabe 2/2024
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI: https://doi.org/10.1007/s12181-024-00669-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Interventioneller Vorhofohrverschluss: Restleckagen müssen vermieden werden!

Übersterblichkeit im Kontext der COVID-19-Pandemie in Deutschland

Systemerkrankung Herzinsuffizienz

Professioneller Umgang mit sozialen Medien in der Kardiologie

Übersicht zur Katheterablation ventrikulärer Arrhythmien